

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC20170002399		Fecha de Prioridad: 6 de diciembre de 2013		
CRITERIOS PARA LA BÚSQUEDA				
Palabras clave utilizadas		composition AND bioactive AND agent AND particles AND dispers* AND oil AND droplets AND matrix AND enteric AND coating AND polymer AND mucoadhesive AND polymer		
		composition AND bioactive AND particles AND oil AND droplets AND enteric AND mucoadhesive		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K9/16 OR A61K9/18 OR A61K47/38 OR A61K47/30		
DOCUMENTOS CONSIDERADOS RELEVANTES				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	Ninguna	---	---	---
ISA/IPEA	US2012141585	2012	párrs [0098]-[0102]	X
EPO (Suplementaria)	WO2005115341	08/12/2005	1,6-11,13-17 párrs [0034], [0056], [0057], [0060], [0128], [0237]; reivs 1, 17, 18, 22, 36, 74	X
			Reivs 1-17	Y
	WO2011152783	08/12/2011	1-8,10-16 págs 16 - 17; reivs 1-14	X
			Reivs 1-17	Y
USPTO	No han buscado			
Patbase	---	---	---	---
Google Patents	US20030157326	21/08/2003	---	---
ORBIT	WO2010133609	25/11/2010	Párrs (0014), (0026), (0139), (0216), (0235), (0246), (0172), (0179); reivs 1,45	X
STN	WO2013166385	07/11/2013	---	A
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.			“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.	
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente	
-----------------------	--

Fecha del reporte de búsqueda:	27 de septiembre de 2018
--------------------------------	--------------------------

Pat Base



Menu ▾ Search ▾ History ▾ Session ▾ Folder ▾ Order Help ▾ Logoff

Search 1: TAC=(composition AND bioactive AND agent AND particles AND dispers* AND oil AND droplets AND matrix AND enteric AND coating AND polymer AND mucoadhesive AND polymer) and IC=(A61K9/16 OR A61K9/18 OR A61K47/38 OR A61K47/30) Explore se

Results 1

#	Search query	Results	Options
1	TAC=(composition AND bioactive AND agent AND particles AND dispers* AND oil AND droplets AND matrix AND enteric AND coating AND polymer AND mucoadhesive AND polymer) and IC=(A61K9/16 OR A61K9/18 OR A61K47/38 OR A61K47/30)	1	View Browse Hits Optimise more...

Google Patents



composition AND bioactive AND agent AND particles AND dispers* AND o   

SEARCH TERMS ⓘ ×

composition AND bioactive AND agent AND particles AND dispers* AND oil AND droplets AND matrix AND enteric AND coating AND polymer AND mucoadhesive AND polymer AND (A61K9/16 OR A61K9/18 OR A61K47/38 OR A61K47/30) ×

OR + Synonym

+ Synonym

SEARCH FIELDS

 Date · Priority ▾
YYYY-MM-DD — YYYY-MM-DD

 + Inventor

 + Assignee

Patent Office ▾ Language ▾

Status ▾ Type ▾

About 37 results

Sort by · Relevance ▾ Grouped by · None ▾ Results / page · 10 ▾

Microcapsule matrix microspheres, absorption-enhancing pharmaceutical ...



US · [Application US20030157326A1](#) · Farid Vaghefi · Verion Inc.
Priority 2001-04-27 · Filing 2002-10-18 · Publication 2003-08-21
The present invention relates to microspheres, processes for the manufacture of said microspheres, pharmaceutical compositions comprising said microspheres, and sustained release methods of administering an effective pharmaceutical amount of a bioactive compound to a subject. The microspheres of ...

Drugs And Gene Carrier Particles That Rapidly Move Through Mucous Barriers

EP US WO · [Application US20080166414A1](#) · Justin Hanes · Johns Hopkins University
Priority 2004-01-28 · Filing 2005-01-28 · Publication 2008-07-10
The invention generally relates to polymeric particles suitable for transporting bioactive agents across mucosal barriers. The invention also relates to methods of making and using those polymeric particles.

Immunomodulatory compositions comprising a polymer matrix and an oil phase

CA CN EP GB JP US WO · [Application WO2011018504A2](#) · Ivan Coulter · Sigmoid Pharma Limited
Priority 2009-08-12 · Filing 2010-08-12 · Publication 2011-02-17
A pharmaceutical composition comprising a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising at least one immunomodulator selected from an adjuvant, an antigen or a combination thereof. A method of manufacturing shaped compositions comprises mixing an ...

Compositions and methods relating to reduced mucoadhesion



CA EP US WO · [Application US20120121718A1](#) · Samuel K. Lai · The Johns Hopkins University
Priority 2010-11-05 · Filing 2011-11-04 · Publication 2012-05-17
The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene

ORBIT

Easy search

Menu Filter Explorer <<

Filter options

150 results for (composition AND bioactive AND particles AND oil AND droplets AND enteric AND mucoadhesive AND vaccine)/TI/AB/IW/CLMS/DESC/ODES/OBJ/TX - Collection: FAMPAT

#	Title	Publication number	1st app. date	Applicant/Assignee	Relevance
1	Composition for oral delivery of bioactive agents	CA2932681	2014-11-20	ADVANCED BI...	100 %
2	Composition comprising oil drops	WO2010113669	2010-05-18	SIGMOID PHA...	99 %
3	Immunomodulatory compositions comprising a polymer matrix and an oil phase	WO2010118504	2010-08-12	SIGMOID PHA...	99 %
4	Mucoadhesive nanoparticle delivery system	CA2877051	2013-06-20	SHEN YANG A...	99 %
5	Nanemulsion vaccines	US20030194412	2002-06-05	UNIVERSITY O...	98 %
6	Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells	US20102207754	2012-02-15	BAXION THER...	98 %
7	Pharmaceutical composition of nanoparticles	US8354094	2012-08-20	NANOMEGA M...	98 %
8	Pharmaceutical composition of nanoparticles	US8574544	2012-12-21	NANOMEGA M...	98 %
9	Compositions and methods relating to reduced mucoadhesion	WO2012061703	2011-11-04	JOHNS HOPKI...	98 %
10	Composition for delivery of active agents to an animal	CA2990190	2016-06-23	ADVANCED BI...	97 %
11	Drugs and gene carrier particles that rapidly move through mucous barriers	WO2005072710	2005-01-28	JOHNS HOPKI...	97 %
12	pH-responsive mucoadhesive polymeric encapsulated microorganisms	US201070165201	2016-12-08	MIT - MASSAC...	97 %
13	A pharmaceutical composition of nanoparticles	WO2011133198	2011-01-31	NANOMEGA M...	97 %
14	Pharmaceutical nanoparticles showing improved mucosal transport	CA2871778	2013-05-03	JOHN HOPKIN...	97 %

STN

STN Projects Working On – SPTSO

Welcome, Olga Rosa Gonzalez Fonseca Layout ▾ Settings STN Help ▾ Contact Us Sign Out ▾

CAPLUS, MARPAT, REGISTRY, INPADOC, PCTFULL, USF...

Enter your query...

Submit

QUERIES (3) STRUCTURES (0) SAVED (0)

Expand All Collapse All

	INPADOC	MARPAT	PCTFULL	USFULL
	1	0	166	359

composition AND bioactive AND particles AND oil AND droplets AND enteric AND mucadhesives
CAPLUS, REGISTRY, MARPAT, INPADOC, PCTFULL, USFULL

	CAPLUS	REGISTRY	INPADOC	MARPAT	PCTFULL	USFULL
	1	10	1	0	166	359

L3 COUNTS RESULTS

CAPLUS (1) REGISTRY (10) MARPAT (0) INPADOC (1) PCTFULL (166) USFULL (359)

Sort by: Publication Date Display: 100 page 1 of 2

36. WO/A1 (2013) PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT
Compositions with improved particle transport in mucus are provided. In some embodiments, the **compositions** and methods involve making mucus-penetrating **particles** (MPF) ...
37. WO/A1 (2013) ANTI-CD22 ANTIBODIES
... one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic **compositions**, methods and devices.
38. WO/A1 (2013) NANOPARTICLES FOR TREATMENT OF ALLERGY
The present invention encompasses the surprising finding that nanoparticle **compositions** can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such ...
39. WO/A1 (2013) ADJUVANT AND VACCINE COMPOSITIONS
Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin, polymer and one or more additives. The polymer is preferably polyacrylic acid-based. The additive is preferably one or more of a glycoside and a sterol. The method ...
40. WO/A1 (2012) THERAPEUTIC COMPOSITIONS AND METHODS FOR ANTIBODY AND FC-CONTAINING TARGETING MOLECULE-BASED TARGETED DELIVERY OF BIOACTIVE MOLECULES BY BACTERIAL MINICELLS
The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling ...
41. WO/A1 (2012) PULMONARY ADMINISTRATION OF RIFAZALIL AND ANALOGS THEREOF
Methods for treating bacterial lung infections, such as tuberculous infections, using a poorly absorbable form of rifazalil, are described. **Compositions** for pulmonary administration of a non-microgranulated rifazalil formulation are also described. In one embodiment, the patients that are treated are ...
42. WO/A1 (2012) COMPOSITIONS AND METHODS RELATING TO REDUCED MUCCADHESION
The present invention generally relates to reducing the **mucadhesive** properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol)- (poly(propylene oxide))-poly(ethylene ...
43. WO/A2 (2011) ANTI-GD2 ANTIBODIES
... affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or **compositions** thereof for the detection,